← stocks-llm New chat

FOGHORN THERAPEUTICS INC (FHTX) — insider trading

Health Care · NASDAQ

FOGHORN THERAPEUTICS INC (FHTX) has 14 reported SEC Form 4 insider transactions in our data (latest 2026-06-24).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-06-24 Cole Douglas G. Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 PARSHALL B LYNNE Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 GILL SIMBA Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 SMITH IAN F Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 Mendelsohn Michael Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 Gallagher Neil Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 Biller Scott Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 Duty Stuart Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-06-24 Lynch Thomas J. Jr. Director Grant / award / vesting (derivative) 28,000 $4.08 $114.2K Form 4
2026-04-10 GOTTSCHALK ADRIAN Director, Officer (Chief Executive Officer) Bona fide gift 59,208 $0.00 $0 Form 4
2026-04-10 GOTTSCHALK ADRIAN Director, Officer (Chief Executive Officer) Bona fide gift 59,208 $0.00 $0 Form 4
2026-04-09 GOTTSCHALK ADRIAN Director, Officer (Chief Executive Officer) Bona fide gift 47,497 $0.00 $0 Form 4
2026-04-09 GOTTSCHALK ADRIAN Director, Officer (Chief Executive Officer) Bona fide gift 47,497 $0.00 $0 Form 4
2026-02-23 Maynard Ryan D Officer (Chief Financial Officer) Grant / award / vesting (derivative) 400,000 $5.75 $2.30M Form 4

Ask the chat about FHTX's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: FOGHORN THERAPEUTICS INC (FHTX).

Last updated 2026-06-24 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.